← All trials
NCT01069965
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 1, 2010
- Primary completion
- Aug 1, 2011
- Completion date
- Oct 1, 2011
- First posted
- —
- Last posted
- —
- Enrollment
- 196
- Arms / groups
- 6 / —
- Source
- AACT · pre-existing
Sponsors
- N-Gene Research Laboratories, Inc.Lead sponsor
- University of CologneOverall official - principal investigator
- Drug Research Center, Balatonfured, HungaryOverall official - principal investigator
- Kinexum LLCStudy director
- IntegriumCollaborator
- Msource Medical Development GmbHCollaborator
- Kinexum LLCCollaborator
- Thermo Fisher ScientificCollaborator
- Barc NVCollaborator
- Georgetown UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.